Clinical trials: sponsored by Mario Negri Institute for Pharmacological Research
- Lead sponsor (exact) Mario Negri Institute for Pharmacological Research
- Age group Children (under 18)
Glomerulopathy, C3G
Pilot STUDY to Monitor Ex-vivo the Biological Effects of the C3 Inhibitor, PEGCETACOPLAN, on Activation of Complement in Fluid Phase and on Podocytes in Patients With C3G and Primary IC-MPGN
This is a prospective, multicenter, non-interventional, observational pharmacological real-world study to characterize longitudinal changes in ex vivo biomarkers of complement activation in patients with C3G and primary IC-MPGN…
- Conditions
- Glomerulopathy, C3G, Membranoproliferative Glomerulonephritis (MPGN)
- Trial name
- COMPASS (NCT07904338)
- Testing
- Blood sample
- Where
- Italy
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Mario Negri Institute for Pharmacological Research
Semi-intensive Care Unit, Evaluation
Health-care Quality in Semi-intensive Care Units
The main aim of this study is to realize a system of continuous evaluation of healthcare quality in semi-intensive care units.
- Conditions
- Semi-intensive Care Unit, Evaluation, Quality
- Trial name
- NCT04676347
- Where
- 18 sites in Italy
- Volunteers
- 39,000 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Emergency Department, Crowding
A New Crowding Indicator in the Emergency Department
Fenice has proposed a new indicator to measure the level of crowding in the ER. The aim of this study is to evaluate, in a national multicenter context, the degree of agreement between the Fenice indicator and the perception of…
- Trial name
- NCT07111624
- Where
- 52 sites in Italy
- Volunteers
- 828 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
A Possible Founding PKD2 Mutation Associated With Variable Phenotypes of ADPKD in Bergamo Province
This is an observational study aimed at assessing if a new and specific heterozygous deletion detected at PKD2 gene is associated to a "founder effect" in 10 Autosomal dominant polycystic kidney disease (ADPKD) patients, and at…
- Trial name
- POPULAR (NCT06594367)
- Where
- Italy
- Volunteers
- 10 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Atypical Hemolytic Uremic Syndrome, Membranoproliferative Glomerulonephritis
Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare Diseases
This project aims to identify, through RNA-Seq technology, the genetic alterations underlying undiagnosed rare diseases in pediatric and adult patients with early onset and with negative WES.
- Conditions
- Atypical Hemolytic Uremic Syndrome, Membranoproliferative Glomerulonephritis, Autosomal Dominant Polycystic Kidney, Healthy
- Trial name
- ANTHEM (NCT05996731)
- Testing
- Skin biopsy
- Where
- Italy
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Mario Negri Institute for Pharmacological Research
Hemolytic-Uremic Syndrome, Membranoproliferative Glomerulonephritis
New Analytic Tools for aHUS and C3G Diagnosis
This protocol is part of a larger project, COMPRare (COMPlement-mediated Rare kidney diseases), which has been financed on behalf of the EJP RD (European Joint Programme on Rare Diseases) program of EU and is leaded by a…
- Conditions
- Hemolytic-Uremic Syndrome, Membranoproliferative Glomerulonephritis, Healthy
- Trial name
- COMPRare (NCT05985122)
- Testing
- C3NEF assay
- Where
- Italy
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Mario Negri Institute for Pharmacological Research
Childhood Obesity
MuLtidimensional School-based and Family interVentions to Promote hEalthy and Sustainable LifestYle for the Childhood
Childhood obesity condition has increased 10 times in the last 40 years, representing one of the most important public health challenges of our century.
- Trial name
- LIVELY (NCT05966051)
- Testing
- Educational interventions
- Where
- Italy
- Volunteers
- 226 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Atypical Hemolytic Uremic Syndrome
Functional Implications of Rare Gene Mutations in aHUS Open the Door to Personalized Therapy
Hemolytic Uremic Syndrome (HUS) is a rare disease characterized by rupture of red blood cells (hemolytic anemia), low platelet count (thrombocytopenia), and thrombotic occlusion of small vessels (thrombotic microangiopathy), with…
- Trial name
- aHUS-iPSC-EC (NCT05805202)
- Testing
- Blood sampling and urine analysis
- Where
- Italy
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Mario Negri Institute for Pharmacological Research
Peripheral Artery Disease
Peripheral Artery Disease in Patients With Stable Coronary Artery Disease in General Practice: Prevalence, Management and Clinical Outcomes.
Patients with lower extremity peripheral artery disease (PAD) are at risk of developing major adverse limb events and have a similar cardiovascular (CV) morbidity and mortality to those with coronary artery disease (CAD) with…
- Trial name
- PAD&CAD (NCT03921905)
- Testing
- ABI measurement
- Where
- 4 sites in Italy
- Volunteers
- 713 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Nephrotic Syndrome
B Cells in Idiopathic Nephrotic Syndrome
The main aim of the present study is to determine whether reconstitution of different B-cell subpopulations can predict relapse after treatment with B-cell depleting antibodies in adult with NS, and whether specific B- or T-cell…
- Trial name
- BLADE (NCT05712369)
- Testing
- Blood sampling
- Where
- Italy
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Mario Negri Institute for Pharmacological Research
Social Determinants of Health, Health Knowledge, Attitudes, Practice
NASCITA Italian Birth Cohort Study
The NASCITA study (NAscere e creSCere in ITAlia) was created to improve the understanding of the health status of Italian children early on and how it is affected by social and health determinants.
- Conditions
- Social Determinants of Health, Health Knowledge, Attitudes, Practice, Development, Child, Mental Disorders
- Trial name
- NASCITA (NCT03894566)
- Testing
- No intervention - birth cohort study
- Where
- Italy
- Volunteers
- 5,000 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
End-Stage Renal Disease
Artificial Intelligence-based Techniques to Characterize KIdney Microstructure on Histological ImagEs
The primary aim of this observational exploratory study will be to use fully anonymized histological images of kidney human tissue from patients with any kidney disease and normal kidney tissue to develop novel deep…
- Trial name
- AI-TIME (NCT06690190)
- Where
- Italy
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Mario Negri Institute for Pharmacological Research
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Artificial Intelligence-based Image Processing Methods to Advance the Characterization of Polycystic Kidney Disease
The primary aim of this observational exploratory study is to develop AI-based image processing methods to advance the characterization of Polycystic Kidney Disease using medical images and associated clinical data, including: 1.
- Trial name
- AI4PKD (NCT06688981)
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Alport Syndrome
Effects of an Intensified Treatment With ACE-I,ATA II and Statins in Alport Syndrome
Alport syndrome (AS) represents a form of progressive hereditary nephritis in which the genetic defect resides in the synthesis of one of several subunits of type IV collagen, the predominant constituent of basement membranes in…
- Trial name
- NCT00309257
- Testing
- ACE I, ATA II and Statins, Benazepril, Valsartan and Fluvastatin
- Where
- Italy
- Volunteers
- 9 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Nephrolithiasis
Genetic Study of Nephrolithiasis in Gouty Diathesis
Gouty diathesis describes uric acid or calcium oxalate nephrolithiasis and low urinary pH (<5.5). A hereditary component has been outlined for several forms of nephrolithiasis (such as hypercalciuria, hyperoxaluria, cystinuria…
- Trial name
- NCT00149305
- Testing
- Genetic analyses
- Where
- Italy
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Mario Negri Institute for Pharmacological Research
C3 Glomerulonephritis, C3 Glomerulopathy
Non-contrast Enhanced MRI in Patients With C3 Glomerulopathy (C3G) or Immune-complex Membranoproliferative Glomerulonephritis (IC-MPGN) Enrolled in the ACH471-205 Study
Functional and quantitative renal magnetic resonance imaging (MRI) has seen a number of recent advances, and techniques are now available that can generate quantitative imaging biomarkers with the potential to improve the…
- Conditions
- C3 Glomerulonephritis, C3 Glomerulopathy, Immune Complex Membranoproliferative Glomerulonephritis, IC-MPGN
- Trial name
- NCT03723512
- Testing
- Non contrast-enhanced magnetic resonance imaging
- Where
- Italy
- Volunteers
- 7 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Atypical Hemolytic Uremic Syndrome
Eculizumab to Cemdisiran Switch in aHUS
Atypical Hemolytic Uremic Syndrome (aHUS) is a rare, lifethreatening, chronic disease of complement-mediated thrombotic microangiopathy (TMA) characterized by acute onset of renal impairment, thrombocytopenia, and…
- Trial name
- DANCE (NCT03999840)
- Testing
- cemdisiran
- Where
- Italy
- Sponsor
- Mario Negri Institute for Pharmacological Research
Second Hand Tobacco Smoke
The TackSHS Survey: a Pan-European Study on SHS
Within the TackSHS project (H2020 project grant agreement No 681040), we will conduct a European cross-sectional study, aiming at i) estimating prevalence and investigating determinants of smoking, e-cigarette use and exposure to…
- Trial name
- NCT02928536
- Testing
- no intervention
- Where
- Italy
- Volunteers
- 11,902 people, healthy volunteers welcome
- Sponsor
- Mario Negri Institute for Pharmacological Research
Membranoproliferative Glomerulonephritis
Eculizumab in Primary MPGN
Membranoproliferative glomerulonephritis (MPGN) is the third or fourth leading cause of end stage renal disease among the primary glomerulonephritis.
- Trial name
- EAGLE (NCT02093533)
- Testing
- Eculizumab
- Where
- 13 sites in Italy
- Volunteers
- 10 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Fabry Disease
Enzyme Replacement Therapy in Fabry Disease
Fabry disease is an X-linked rare metabolic disease, caused by a deficient activity of the hydrolase α-Galactosidase A, and characterized by a progressive and systematic deposition of glycosphingolipids in many organs.
- Trial name
- NCT00149318
- Testing
- Biochemical analyses.
- Where
- Italy
- Volunteers
- 2 people
- Sponsor
- Mario Negri Institute for Pharmacological Research